Results 101 to 110 of about 602,416 (352)

Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

SLAS discovery : advancing life sciences R & D, 2020
The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody–drug conjugates (ADCs), in which biologically active drugs are coupled through chemical ...
Laurence Gauzy-Lazo, I. Sassoon, Marie-Priscille Brun   +2 more
semanticscholar   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Antibody Drug Conjugates for Cancer Therapy

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017
BACKGROUND AND OBJECTIVE: In recent decades, the use of antibody drugs conjugates (ADCs) generated promise for the treatment of cancer. In this type of treatment, a monoclonal antibody against a cancer specific antigen is used, and a cytotoxic drug is ...
S M Gheibi hayat, AH Sahebkar
doaj  

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Blood Cancer Journal, 2019
Interim analyses of a phase I study with GSK2857916, an antibody–drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM).
S. Trudel, N. Lendvai, R. Popat, P. Voorhees, B. Reeves, E. Libby, P. Richardson, A. Hoos, I. Gupta, V. Bragulat, Zangdong He, J. Opalinska, A. Cohen   +12 more
semanticscholar   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

The effects of zinc sulfate on ethyl glucuronide immunoassay urine testing [PDF]

, 2016
Published research in the Journal of Analytical Toxicology and the American Society for Clinical Pathology has confirmed that the presence of Zinc Sulfate in adulterated urine samples can influence the testing results using EMIT and ELISA immunoassay ...
Cawley, Shanna Marie
core   +1 more source

Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan [PDF]

, 2015
The aim of this overview is to review the evolution of the studies carried out, during more than 25 years, on nanohydrogels obtained by self-assembling of pullulan (PUL) using several hydrophobization strategies.
ALHAIQUE, Franco, COVIELLO, Tommasina, DI MEO, Chiara, MATRICARDI, PIETRO, MONTANARI, ELITA   +4 more
core   +1 more source

Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.

Chemical and pharmaceutical bulletin, 2020
Auristatins are important payloads used in antibody drug conjugates (ADCs), and the most well-known compound family member, monomethyl auristatin (MMAE), is used in two Food and Drug Administration (FDA)-approved ADCs, Adcetris® and Polivy®.
Michinori Akaiwa, Julien Dugal-Tessier, B. Mendelsohn   +2 more
semanticscholar   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source